University of Alberta has divulged 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of viral infections.
Sail Biomedicines Inc. has received two grants from the Bill & Melinda Gates Foundation to advance the company's Endless RNA (eRNA) platform to develop secreted monoclonal antibodies and vaccines for malaria.
Researchers have identified a new class of antibiotics that works by blocking the transportation of lipopolysaccharide (LPS) to the outer membrane of the gram-negative bacterium Acinetobacter baumannii. The most advanced member of the class, zosurabalpin (RG-6006, Roche AG), was effective against multiple A. baumannii strains, including carbapenem-resistant and multidrug-resistant strains.
Ubidx Inc. has designed a diagnostic system comprised of a fluidic single-use disposable and a base. While the fluidic single-use disposable or cartridge is generally described as being suitable for testing a single sample, the base or hub may be used numerous times to perform numerous tests using numerous fluidic single-use disposables or cartridges.
Acinetobacter baumannii, a gram-negative opportunistic bacteria causing nosocomial bloodstream, urinary tract and airway infections, poses a high disease burden worldwide, particularly in Sub-Saharan Africa. Moreover, A. baumannii is a multidrug resistance (MDR) critical priority pathogen that could contribute up to 10 million deaths annually by 2050. Therefore, novel antibiotic approaches to treat MDR A. baumannii constitute a critical medical need.
Janssen R&D (Ireland) has identified compounds acting as viral fusion inhibitors and reported to be useful for the treatment of respiratory syncytial virus (RSV) infections.
It is not the first malaria vaccine, but R21, recommended for use by the World Health Organization in October, is the first that can be manufactured at modest cost and the sort of scale needed for widespread prevention of the killer disease in Africa.
Jiangxi Jemincare Group Co. Ltd. has reported that its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co. Ltd., recently received approvals for clinical trials of five of its drugs in the fields of cancer, kidney and infectious diseases.
A team of researchers at Monash University, Swiss Tropical & Public Health Institute and the University of Nebraska have prepared aryl hydantoin compounds for the treatment of schistosomiasis.
RSS
